HyperBiota
Financiado
Exploring the diet microbiota axis for immunomodulation and organ protection in...
Exploring the diet microbiota axis for immunomodulation and organ protection in hypertension
Essential hypertension damages organs such as the kidney, thereby leading to premature death. Beyond elevated blood pressure, hypertension is characterized by a pro-inflammatory immune response ahead of measurable organ damage. Ac...
Essential hypertension damages organs such as the kidney, thereby leading to premature death. Beyond elevated blood pressure, hypertension is characterized by a pro-inflammatory immune response ahead of measurable organ damage. Activated immune cells infiltrate the kidney to cause tissue injury. However, inflammation is insufficiently addressed by today’s drugs. Current treatments do not include the gut microbiota, its metabolites and the associated lymphoid tissue – the largest immune cell reservoir in the body. We have recently shown for the first time that variations in dietary salt intake promote hypertension by modulating the immune system via the microbiota and its metabolites. Thus, the diet-microbiota axis is an important modulator of the immune response in hypertension. HyperBiota envisions a personalized, microbiome-guided immunonutrition for anti-inflammatory immunomodulation and organ protection in hypertension. It will explore the interplay between diet-dependent microbial metabolism in the intestine and the immune system in hypertension. By using an interdisciplinary approach, HyperBiota aims to 1) decipher the reciprocity of dietary composition, microbial community structure and metabolism, and immune response in hypertension. The identification of critical dietary and microbial components will enable targeted interventions. 2) Particular attention will be payed to worsening kidney function and how this affects microbial ecology and immune cell homeostasis. 3) It will investigate the extent to which the gut-associated lymphoid tissue contributes to the immune response in hypertension and its responsiveness to targeted interventions. 4) Knowledge gained in model systems will be translated and verified in mice associated with human microbial communities. Taking this approach, HyperBiota will cross borders and take a systems view on inflammation in hypertension to enable microbiome-guided immunonutrition for organ protection in hypertension.
ver más
Duración del proyecto: 62 meses
Fecha Inicio: 2019-11-12
Fecha Fin: 2025-01-31
Fecha Fin: 2025-01-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-11-12
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2019-STG:
ERC Starting Grant
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
1M€
Líder del proyecto
CHARITE UNIVERSITAETSMEDIZIN BERLIN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
745.42K€ |
Participante